LITTLE KNOWN FACTS ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS.

In Section A, individuals will receive distinctive doses and schedules of oral ABBV-744 pill to recognize Protected dosing program. Added individuals will probably be enrolled at the determined monotherapy dosign regimen. In Phase B, individuals will acquire oral ruxolitinib and ABBV-744 will probably be offered as "add-on" therapy. In Section C, p